This is a working overview of single-use aliquot, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-15 and is reviewed periodically as new material appears.
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White lyophilized powder | Typical for synthetic peptides |
| Solubility | Freely soluble in water | Also soluble in saline |
| Storage temperature | -20 C or below | Protect from repeated freeze-thaw |
| Analytical method | Reverse-phase HPLC | Confirms purity and identity |
| Common synonym | ACTH(4-10) analog | Reflects structural origin |
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
== Budget == For the 2026 fiscal year, CLIA was budgeted US$25.2 million. The approximately 86 surveyors conduct 120 surveys annually, 112 initial/recertification and eight follow-up surveys, spending an average of up to 14 hours per survey. The staffing ratio is one clerk per three surveyors, one professional support staff per six surveyors, and one supervisory surveyor per seven surveyors. The projected workload is 7,933 compliance initial and recertification surveys, 2505 follow-up/revisit surveys of compliance laboratories, 393 validations of accredited laboratories, 92 follow-up/revisit surveys of accredited laboratories, 215 complaint surveys, and 725 proficiency testing desk reviews. The Waived Laboratory Survey Initiative is discontinued, and CLIA waivers are no longer available; PPM laboratories will not receive routine inspections.
Solid supports for peptide synthesis are selected for physical stability, to permit the rapid filtration of liquids. Suitable supports are inert to reagents and solvents used during SPPS and allow for the attachment of the first amino acid. Swelling is of great importance because peptide synthesis takes place within the solvent-swollen resin beads. The primary type of solid supports is suspension polymerized copoly(1% m-divinyl + styrene)beaded resin. Improvements to solid supports used for peptide synthesis enhance their ability to withstand the repeated use of TFA during the deprotection step of SPPS. Two primary resins are used, based on whether a C-terminal carboxylic acid or amide is desired. The Wang resin was, as of 1996, the most commonly used resin for peptides with C-terminal carboxylic acids.
== History == The association of elevated intraocular pressure (IOP) and glaucoma was first described by Englishman Richard Banister in 1622: "...that the Eye be grown more solid and hard, then naturally it should be...". Angle-closure glaucoma was treated with cataract extraction by John Collins Warren in Boston as early as 1806. The invention of the ophthalmoscope by Hermann Helmholtz in 1851 enabled ophthalmologists for the first time to identify the pathological hallmark of glaucoma, the excavation of the optic nerve head due to retinal ganglion cell loss. The first reliable instrument to measure intraocular pressure was invented by Norwegian ophthalmologist Hjalmar August Schiøtz in 1905. About half a century later, Hans Goldmann in Bern, Switzerland, developed his applanation tonometer, which, still today, despite numerous innovations in diagnostics, is considered the gold standard of determining this crucial pathogenic factor. In the late 20th century, further pathomechanisms beyond elevated IOP were discovered and became the subject of research, like insufficient blood supply, often associated with low or irregular blood pressure, to the retina and optic nerve head. The first drug to reduce IOP, pilocarpine, was introduced in the 1870s; other major innovations in pharmacological glaucoma therapy were the introduction of beta blocker eye drops in the 1970s and of prostaglandin analogues and topical (locally administered) carbonic anhydrase inhibitors in the mid-1990s.
== Classification == There are two typing systems for OI in modern use. The first, created by David Sillence in 1979, classifies patients into four types, or syndromes, according to their clinical presentation, without taking into account the genetic cause of their disease. The second system expands on the Sillence model, but assigns new numbered types genetically as they are found. Therefore, people with OI can be described as having both a clinical type and a genetic type, which may or may not be equivalent. Type I is the most common, and 90% of cases result from mutations to either COL1A1 or COL1A2. Symptoms vary widely between types, as well as vary from person to person, even in the same family. As of 2021, 21 types of OI have been defined:
Sources: en.wikipedia.org
==== Keratan sulfate ==== Keratan sulfates have a variable sulfate content and, unlike many other GAGs, do not contain uronic acid. They are present in the cornea, cartilage, bones, and the horns of animals.
Collagen induction therapy (CIT), also known as microneedling, dermarolling, or skin needling, is a cosmetic procedure that involves repeatedly puncturing the skin with tiny, sterile needles (microneedling the skin). It is important to distinguish CIT from other contexts in which microneedling devices are used on the skin (e.g., transdermal drug delivery, vaccination). It is a technique for which research is ongoing, but has been used for a number of skin problems including scarring and acne. Some studies have also shown that when combined with minoxidil treatment, microneedling is able to treat hair loss more effectively than minoxidil treatment alone.
While thorium was discovered in 1828 its first application dates only from 1885, when Austrian chemist Carl Auer von Welsbach invented the gas mantle, a portable source of light which produces light from the incandescence of thorium oxide when heated by burning gaseous fuels. Many applications were subsequently found for thorium and its compounds, including ceramics, carbon arc lamps, heat-resistant crucibles, and as catalysts for industrial chemical reactions such as the oxidation of ammonia to nitric acid.
Sources: en.wikipedia.org
Cyclohexanehexathione is a cyclic covalent compound consisting of a six-carbon ring with a sulfur bonded to each. It has been generated by neutralization of its monoanion (C6S−6) in a mass spectrometer. This compound is the thioketone analog of cyclohexanehexone; that oxygen variant is expected to be substantially less stable. Synthesis of C6S6 by photolysis or pyrolysis to extrude three equivalents of carbon monoxide from a precursor containing adjacent pairs of sulfurs as cyclic dithiocarbonate units gave what is more likely a different valence isomer, as various dithiete-containing structures are predicted to be more stable than the hexathione form.
=== Influence of Vladimir Cerrón === Vladimir Cerrón is the General Secretary of Free Peru, who represents the Marxist–Leninist faction of the party. Cerrón was previously the governor of Junín, but was convicted for corruption and given a suspended sentence. Cerrón has repeatedly denied such charges, stating that he's a victim of lawfare and political persecution. The indictment prevents Cerrón from running for public office. During the 2021 Peruvian general election, Castillo distanced himself from Cerrón, saying that Cerrón "will not even be a doorman in any of the institutions of the State." However, Castillo has been accused of appointing government officials and ministers who are close to Cerrón. These include the appointment of Waldemar Cerrón, Vladimir's brother, as Free Peru's spokesman in Congress, despite Waldemar being investigated for money laundering. Waldemar has also been under investigation in Los Dinámicos del Centro, an alleged criminal organization that's investigated for money laundering. The investigations also include Vladimir and then Prime Minister Bellido. Vladimir has accused the investigations of being political persecution. Later, a number of alleged members of Los Dinámicos del Centro escaped from the country. Prime Minister Mirtha Vásquez stated that they have been included in Peru's registry of most wanted fugitives.
==== Decomposition of mass ==== In order to quickly generate a manageable number of molecular formula candidates, the monoisotopic mass is decomposed into all possible molecular formulas that would lead to this mass. There are two definitions of the monoisotopic mass: (1) the sum of the masses of the most abundant naturally occurring stable isotope of each atom (i.e. the highest peak of the isotope pattern) (2) the sum of the masses of the lightest naturally occurring stable isotope of each atom (i.e. the peak of the isotope pattern with the lowest mass). For small molecules, the lightest peak is also mostly the highest peak of the isotope pattern. However, in the computational context of SIRIUS, the second definition is used. Decomposing the monoisotopic mass into all possible molecular formulas requires a mass interval taking into account the measurement inaccuracy of the instrument. This real-valued decomposition is transformed into a problem instance with integer masses by using a blowup factor. The resulting problem is known as Change-making problem which is well-studied and can be solved in runtime linear in the size of the output.
=== Pharmacodynamics === AM-1235 is a cannabinoid receptor agonist with Ki of 1.5 nM at CB1 compared to 20.4 nM at CB2. While the 6-nitro substitution on the indole ring reduces affinity for both CB1 and CB2 relative to the unsubstituted parent compound AM-2201, CB2 affinity is reduced much more, resulting in a CB1 selectivity of around 13 times. This is in contrast to other related compounds such as AM-1221 where a 6-nitro substitution instead confers significant selectivity for CB2.
Sources: en.wikipedia.org
It is associated with the melanocortin receptor family, particularly subtypes found in the central nervous system. This interaction is separate from the adrenal pathway activated by full-length ACTH.
Peptidases degrade the compound within minutes in circulation. This short half-life is one reason nasal delivery is used, placing the substance close to the olfactory and trigeminal pathways.
No large multicenter trials have been published in English-language journals. The existing human evidence consists mainly of smaller studies conducted in Russia, which limits generalization.
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.